TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06548542: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

Sponsor: AbbVie · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 590 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT06548542 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06548542 Rescue Dossier →